Nelarabine
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Arranon, Atriance |
Other names | 506U78 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607077 |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | <25% |
Metabolism | By adenosine deaminase, to 9-β-D-arabinofuranosylguanine |
Elimination half-life | 30 minutes (nelarabine) 3 hours (ara-G) |
Excretion | Kidney |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.170.768 |
Chemical and physical data | |
Formula | C11H15N5O5 |
Molar mass | 297.271 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[4] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.[5] It was later approved in the European Union in October 2005. Complete responses have been achieved with this medication.[medical citation needed]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.
- ^ "Atriance EPAR". European Medicines Agency (EMA). Retrieved 4 December 2020.
- ^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
- ^ Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.
External links
- "Nelarabine". Drug Information Portal. U.S. National Library of Medicine.
- "Nelarabine". NCI Dictionary of Cancer Terms. National Cancer Institute.
- "Nelarabine". National Cancer Institute.